United States News Todas as matérias

Nvidia (NASDAQ:NVDA) announced a $3.5 billion investment in MediaTek through convertible bonds, expanding a partnership focused on AI data centers, consumer computing, and automotive platforms.

Helix Energy Solutions (NYSE:HLX) announced that shareholders approved the proposals required to complete its previously announced all-stock combination with Hornbeck Offshore Services.

Cadrenal Therapeutics (NASDAQ:CVKD) reported a positive outcome from a July 28, 2026 FDA Type D meeting regarding the planned Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.

American Financial Group (NYSE:AFG) completed the previously announced sale of Charleston Harbor Resort & Marina and expects to recognize approximately $125 million in pretax core operating earnings from the transaction.

Ensysce Biosciences (NASDAQ:ENSC) announced completion of enrollment in Part 3 of the PF614-MPAR-102 clinical study, evaluating its MPAR overdose-protection technology for opioid medicines.

Gentex (NASDAQ:GNTX) announced that its Board of Directors declared a third-quarter 2026 cash dividend of $0.12 per share.

C1 Fund (NYSE:CFND) reported second quarter 2026 results with net asset value of $42.63 million, or $6.49 per share, and investments across 11 digital asset services and technology companies.

Mobix Labs (NASDAQ:MOBX) announced a definitive agreement to acquire Vision Aerial, a U.S.-based drone manufacturer focused on aerospace, defense, infrastructure, and other industrial markets.

Construction Partners (NASDAQ:ROAD) announced the acquisition of Asphalt Express Enterprises, a liquid asphalt supply and hauling business serving hot-mix asphalt producers in Oklahoma and northern Texas.

CollPlant (NASDAQ:CLGN) signed a definitive agreement to acquire LightSolver, an Israeli deep-tech company developing pure photonic computing technology centered on its Laser Processing Unit platform.

Axsome Therapeutics (NASDAQ:AXSM) announced that the first patient has been dosed in SUMMIT, a Phase 3 trial evaluating AXS-05 for smoking cessation in adult smokers.

Karyopharm Therapeutics (NASDAQ:KPTI) submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval for XPOVIO (selinexor) combined with ruxolitinib to treat patients with myelofibrosis.

Eli Lilly (NYSE:LLY) reported 52-week results from the Phase 3b TOGETHER-PsO and TOGETHER-PsA trials showing Taltz (ixekizumab) plus Zepbound (tirzepatide) improved outcomes compared with Taltz alone in adults with psoriasis or psoriatic arthritis and overweight or obesity.

SAIC (NASDAQ:SAIC) reported fiscal second quarter 2027 revenue of $1.88 billion, up about 6% year over year, including 5.3% organic growth and approximately $20 million from the SilverEdge acquisition.

Pulsenmore (NASDAQ:PLSM) reported first half 2026 revenue of NIS 6.1 million, approximately $2 million, up 53% year over year, with gross profit also increasing 53% to NIS 2.2 million.

BioLineRx (NASDAQ:BLRX) reported second quarter 2026 results with royalty revenue of $0.3 million and a net loss of $4.3 million, compared with a net loss of $3.9 million in the prior-year period.

SLB (NYSE:SLB) signed an agreement to acquire Kelvion, a provider of thermal management and heat exchange technologies, for approximately $3.4 billion in cash to expand its data center infrastructure business.

Lilly (NYSE:LLY) signed a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, adding precision biologics programs targeting autoimmune and allergic diseases.

Aon (NYSE:AON) signed a definitive agreement to acquire USI from KKR and other shareholders for $17 billion, expanding its U.S. insurance brokerage operations.

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second interim overall survival results from the Phase 3 HERIZON-GEA-01 trial showing Ziihera (zanidatamab-hrii) plus chemotherapy improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma.

GameStop (NYSE:GME) reported preliminary second quarter 2026 results showing expected net income of $290 million to $310 million, compared with $168.6 million in the prior-year period.

BeOne Medicines (NASDAQ:ONC) reported Phase 3 HERIZON-GEA-01 trial results showing ZIIHERA (zanidatamab) plus chemotherapy produced a statistically significant improvement in overall survival compared with trastuzumab plus chemotherapy in first-line treatment of HER2-positive gastroesophageal adenocarcinoma.

IDEAYA Biosciences (NASDAQ:IDYA) reported that an FDA Type C meeting provided guidance for the planned global randomized Phase 3 trial of IDE849, a DLL3-targeting TOP1 antibody-drug conjugate for extensive stage small cell lung cancer.

So-Young (NASDAQ:SY) reported second quarter 2026 revenue of RMB505.2 million, up 33.4% year over year, driven mainly by growth in its branded aesthetic center business.